AT 877

Known as: AT-877, AT877 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1990-2013
01219902013

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
BACKGROUND We have previously demonstrated that long-term inhibition of Rho-kinase ameliorates pulmonary arterial hypertension… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
2001
2001
Fasudil hydrochloride (AT877, hexahydro-1-(5-isoquinolinesulfonyl)-1H-1,4-diazepine hydrochloride, identical to HA1077) inhibits… (More)
Is this relevant?
Review
1998
Review
1998
BACKGROUND AND PURPOSE It has been reported that nimodipine reduces the frequency of secondary ischemia and improves outcome… (More)
Is this relevant?
1994
1994
BACKGROUND AND PURPOSE The efficacy of pretreatment with the recently developed intracellular calcium antagonist AT877 against… (More)
  • figure 1
  • figure 2
  • figure 4
  • figure 3
Is this relevant?
1993
1993
We investigated the effects of AT-877, a Ca2+ antagonist, on rat middle-cerebral artery occlusion. All rats had 6-h ischemia, and… (More)
Is this relevant?
Highly Cited
1992
Highly Cited
1992
With the cooperation of 60 neurosurgical centers in Japan, a prospective randomized placebo-controlled double-blind trial of a… (More)
Is this relevant?
1990
1990
The initial dose-escalating clinical trial of a novel calcium antagonist, AT877, in patients with aneurysmal subarachnoid… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?